284.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$284.09
Aprire:
$284.09
Volume 24 ore:
462.93K
Relative Volume:
0.88
Capitalizzazione di mercato:
$12.69B
Reddito:
$2.99B
Utile/perdita netta:
$1.21B
Rapporto P/E:
11.34
EPS:
25.06
Flusso di cassa netto:
$1.13B
1 W Prestazione:
-2.23%
1M Prestazione:
-9.71%
6M Prestazione:
-21.03%
1 anno Prestazione:
-10.31%
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
284.27 | 12.69B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
17.40 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
156.17 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.38 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
2024-02-05 | Iniziato | Leerink Partners | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2022-12-06 | Iniziato | UBS | Buy |
2022-12-05 | Iniziato | Goldman | Sell |
2022-10-11 | Iniziato | Morgan Stanley | Overweight |
2022-09-20 | Reiterato | BofA Securities | Underperform |
2022-09-19 | Ripresa | Wedbush | Outperform |
2022-02-11 | Iniziato | BTIG Research | Neutral |
2021-07-14 | Aggiornamento | Argus | Hold → Buy |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-09-14 | Ripresa | JP Morgan | Overweight |
2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-12-03 | Iniziato | BofA/Merrill | Underperform |
2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2018-02-22 | Reiterato | Barclays | Underweight |
2018-01-18 | Ripresa | Credit Suisse | Underperform |
2017-12-27 | Reiterato | Wedbush | Outperform |
2017-04-27 | Reiterato | Wedbush | Outperform |
2017-03-30 | Iniziato | UBS | Sell |
2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Treprostinil Saga Continues - JD Supra
United Therapeutics president sells shares worth $3.7 million - MSN
Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World
United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus
Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga
United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus
United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus
Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360
United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Construction underway for new United Therapeutics facility in Stewartville - KTTC News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Mesa Nilda | Director |
Jun 24 '25 |
Sale |
289.99 |
645 |
187,045 |
4,883 |
Giltner Richard | Director |
Jun 24 '25 |
Option Exercise |
175.43 |
5,000 |
877,150 |
22,420 |
Giltner Richard | Director |
Jun 24 '25 |
Sale |
289.60 |
3,036 |
879,214 |
19,384 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):